578 related articles for article (PubMed ID: 22749309)
1. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells.
Itzhaki I; Maizels L; Huber I; Gepstein A; Arbel G; Caspi O; Miller L; Belhassen B; Nof E; Glikson M; Gepstein L
J Am Coll Cardiol; 2012 Sep; 60(11):990-1000. PubMed ID: 22749309
[TBL] [Abstract][Full Text] [Related]
2. Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations.
Kujala K; Paavola J; Lahti A; Larsson K; Pekkanen-Mattila M; Viitasalo M; Lahtinen AM; Toivonen L; Kontula K; Swan H; Laine M; Silvennoinen O; Aalto-Setälä K
PLoS One; 2012; 7(9):e44660. PubMed ID: 22962621
[TBL] [Abstract][Full Text] [Related]
3. Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia.
Sasaki K; Makiyama T; Yoshida Y; Wuriyanghai Y; Kamakura T; Nishiuchi S; Hayano M; Harita T; Yamamoto Y; Kohjitani H; Hirose S; Chen J; Kawamura M; Ohno S; Itoh H; Takeuchi A; Matsuoka S; Miura M; Sumitomo N; Horie M; Yamanaka S; Kimura T
PLoS One; 2016; 11(10):e0164795. PubMed ID: 27764147
[TBL] [Abstract][Full Text] [Related]
4. A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.
Preininger MK; Jha R; Maxwell JT; Wu Q; Singh M; Wang B; Dalal A; Mceachin ZT; Rossoll W; Hales CM; Fischbach PS; Wagner MB; Xu C
Dis Model Mech; 2016 Sep; 9(9):927-39. PubMed ID: 27491078
[TBL] [Abstract][Full Text] [Related]
5. Mutant ryanodine receptors in catecholaminergic polymorphic ventricular tachycardia generate delayed afterdepolarizations due to increased propensity to Ca2+ waves.
Paavola J; Viitasalo M; Laitinen-Forsblom PJ; Pasternack M; Swan H; Tikkanen I; Toivonen L; Kontula K; Laine M
Eur Heart J; 2007 May; 28(9):1135-42. PubMed ID: 17347175
[TBL] [Abstract][Full Text] [Related]
6. Slowed depolarization and irregular repolarization in catecholaminergic polymorphic ventricular tachycardia: a study from cellular Ca2+ transients and action potentials to clinical monophasic action potentials and electrocardiography.
Paavola J; Väänänen H; Larsson K; Penttinen K; Toivonen L; Kontula K; Laine M; Aalto-Setälä K; Swan H; Viitasalo M
Europace; 2016 Oct; 18(10):1599-1607. PubMed ID: 26705554
[TBL] [Abstract][Full Text] [Related]
7. Patient-Specific Drug Screening Using a Human Induced Pluripotent Stem Cell Model of Catecholaminergic Polymorphic Ventricular Tachycardia Type 2.
Maizels L; Huber I; Arbel G; Tijsen AJ; Gepstein A; Khoury A; Gepstein L
Circ Arrhythm Electrophysiol; 2017 Jun; 10(6):. PubMed ID: 28630169
[TBL] [Abstract][Full Text] [Related]
8. Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation.
Sedej S; Heinzel FR; Walther S; Dybkova N; Wakula P; Groborz J; Gronau P; Maier LS; Vos MA; Lai FA; Napolitano C; Priori SG; Kockskämper J; Pieske B
Cardiovasc Res; 2010 Jul; 87(1):50-9. PubMed ID: 20080988
[TBL] [Abstract][Full Text] [Related]
9. Novel Calmodulin Variant p.E46K Associated With Severe Catecholaminergic Polymorphic Ventricular Tachycardia Produces Robust Arrhythmogenicity in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Gao J; Makiyama T; Yamamoto Y; Kobayashi T; Aoki H; Maurissen TL; Wuriyanghai Y; Kashiwa A; Imamura T; Aizawa T; Huang H; Kohjitani H; Nishikawa M; Chonabayashi K; Fukuyama M; Manabe H; Nakau K; Wada T; Kato K; Toyoda F; Yoshida Y; Makita N; Woltjen K; Ohno S; Kurebayashi N; Murayama T; Sakurai T; Horie M; Kimura T
Circ Arrhythm Electrophysiol; 2023 Mar; 16(3):e011387. PubMed ID: 36866681
[TBL] [Abstract][Full Text] [Related]
10. Mutation-specific differences in arrhythmias and drug responses in CPVT patients: simultaneous patch clamp and video imaging of iPSC derived cardiomyocytes.
Pölönen RP; Swan H; Aalto-Setälä K
Mol Biol Rep; 2020 Feb; 47(2):1067-1077. PubMed ID: 31786768
[TBL] [Abstract][Full Text] [Related]
11. Molecular and electrophysiological bases of catecholaminergic polymorphic ventricular tachycardia.
Mohamed U; Napolitano C; Priori SG
J Cardiovasc Electrophysiol; 2007 Jul; 18(7):791-7. PubMed ID: 17578347
[TBL] [Abstract][Full Text] [Related]
12. CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia.
Di Pasquale E; Lodola F; Miragoli M; Denegri M; Avelino-Cruz JE; Buonocore M; Nakahama H; Portararo P; Bloise R; Napolitano C; Condorelli G; Priori SG
Cell Death Dis; 2013 Oct; 4(10):e843. PubMed ID: 24113177
[TBL] [Abstract][Full Text] [Related]
13. Using hiPSC-CMs to Examine Mechanisms of Catecholaminergic Polymorphic Ventricular Tachycardia.
Arslanova A; Shafaattalab S; Ye K; Asghari P; Lin L; Kim B; Roston TM; Hove-Madsen L; Van Petegem F; Sanatani S; Moore E; Lynn F; Søndergaard M; Luo Y; Chen SRW; Tibbits GF
Curr Protoc; 2021 Dec; 1(12):e320. PubMed ID: 34958715
[TBL] [Abstract][Full Text] [Related]
14. Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes.
George CH; Higgs GV; Lai FA
Circ Res; 2003 Sep; 93(6):531-40. PubMed ID: 12919952
[TBL] [Abstract][Full Text] [Related]
15. Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia.
Song L; Alcalai R; Arad M; Wolf CM; Toka O; Conner DA; Berul CI; Eldar M; Seidman CE; Seidman JG
J Clin Invest; 2007 Jul; 117(7):1814-23. PubMed ID: 17607358
[TBL] [Abstract][Full Text] [Related]
16. Modeling of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells.
Caspi O; Huber I; Gepstein A; Arbel G; Maizels L; Boulos M; Gepstein L
Circ Cardiovasc Genet; 2013 Dec; 6(6):557-68. PubMed ID: 24200905
[TBL] [Abstract][Full Text] [Related]
17. Ca2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects.
Zhang XH; Haviland S; Wei H; Sarić T; Fatima A; Hescheler J; Cleemann L; Morad M
Cell Calcium; 2013 Aug; 54(2):57-70. PubMed ID: 23684427
[TBL] [Abstract][Full Text] [Related]
18. Arrhythmogenesis in a catecholaminergic polymorphic ventricular tachycardia mutation that depresses ryanodine receptor function.
Zhao YT; Valdivia CR; Gurrola GB; Powers PP; Willis BC; Moss RL; Jalife J; Valdivia HH
Proc Natl Acad Sci U S A; 2015 Mar; 112(13):E1669-77. PubMed ID: 25775566
[TBL] [Abstract][Full Text] [Related]
19. Catecholaminergic polymorphic ventricular tachycardia: recent mechanistic insights.
Kontula K; Laitinen PJ; Lehtonen A; Toivonen L; Viitasalo M; Swan H
Cardiovasc Res; 2005 Aug; 67(3):379-87. PubMed ID: 15913575
[TBL] [Abstract][Full Text] [Related]
20. TECRL, a new life-threatening inherited arrhythmia gene associated with overlapping clinical features of both LQTS and CPVT.
Devalla HD; Gélinas R; Aburawi EH; Beqqali A; Goyette P; Freund C; Chaix MA; Tadros R; Jiang H; Le Béchec A; Monshouwer-Kloots JJ; Zwetsloot T; Kosmidis G; Latour F; Alikashani A; Hoekstra M; Schlaepfer J; Mummery CL; Stevenson B; Kutalik Z; de Vries AA; Rivard L; Wilde AA; Talajic M; Verkerk AO; Al-Gazali L; Rioux JD; Bhuiyan ZA; Passier R
EMBO Mol Med; 2016 Dec; 8(12):1390-1408. PubMed ID: 27861123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
